We assessed the LKB "Deif Ia" (time-resolved dissociationenhanced lanthanide fluoroimmunoassay) and the Amersham "Amerlite" (enhanced luminescent immunometry) assays of thyrotropin in serum. Both assays are sensitive (respective detection limits: 0.02 and 0.04 milli-int. unit/L) and have very good within-and between-batch precision over a wide range of thyrotropin concentrations. Results by the two methods correlate well (r = 0.992); the regression equation is: Amerlite = 0.915 DeIfia -0.33 milli-int. unit/L. The standard curve for the Delfia assay was linear, but that for the Amerlite assay showed some deviation from linearity below 0.5 milli-int. unitJL. Both assays have a negativebias in comparison with radiolabeled immunoradiometric assays, as judged by results for samples from the Quality Assurance Scheme. Both assays discriminate well between hyper-, hypo-, and euthyroid subjects, and results for thyrotropin for most patients with nonthyroidal illness were within the euthyroid reference interval. Both assays are convenient to perform and are based on systems that provide a viable alternative to radioimmunoassay.
The Amerlite analysis involves a two-step immunometric technique, and two different monoclonal antibodies are also used here, one immobilized on microtiter wells. After unbound conjugate is removed by aspiration and washing at the end ofthe incubation, the horseradish peroxidase (EC 1.11.1.7)-labeled second antibodyismeasured by adding a signal-generated reagent;theresulting signalisread inthe Amerlite analyzer. Many ofthe problems ofusing a luminescentreactionare overcome by using an enhancer that allowslightemissionfrom the enzyme-catalyzed oxidation of luminol to aminophthalic acid to be intensified and emitted as a constantglow overa period oftime.The signalto-noise ratiosare improved because the magnitude ofthe signalproducedin the system is1000 to 1500 times greater than that producedby conventionalluminescence,and the signal is stable for about 20 mm (6).
MaterIals and Methods

Delfia
TSH assay. All assays were performed as recommended by the manufacturer,with a single4-h incubation at a room temperature on a Dynatech Varishaker (speed setting: 5). Briefly described, the method involves the incubation of 50 pL of sample and 200 L of europium-labeled antibody reagent in microtiter wells carrying immobilized anti-TSH antibodies. The wellsare then washed six times with wash solution, and 200 L ofenhancement solution is added.After a further15-mn incubationat room temperaturethe emitted fluorescence ismeasured (excitation at 340 nm, emission at 613 nm) in a time-resolved fluorimeter (Arcus 1230;LKB Wallac,Turku, Finland),with use of a splinecurve-fit program supplied by LKB Wailac. All measurements, curve fitting, and resultcalculations are performed automatically. The standard curve from the assay generatesa wide signalresponse, from 1000 countsfor the zero standard to 3000000 counts in the most concentratedstandard. The assay data are storedon disk,and alterations and recalculations can be made any time after the measurements are complete.
Amerlite TSH assay. All assays were performed as recommended by Amersham International plc, which briefly is as follows. One hundred microliters of assay reagent plus 100 pL of sample are incubated in antibody-coated microtiter wells for 2 h at 37 #{176}C. The wells are then washed in an automated wash station, and 200 pL of conjugate reagent is dispensed into each well. After another 1-h incubation at 37#{176}C the wells are again washed and 250 pL of signal reagent is added. The luminescence is measured in the Amerlite analyzer, all curve fitting and calculation of resuits being performed
automatically. An incubator and automatic washer are supplied as part of the system. The manufacturer stipulates that the luminescence of the wells or edit the results once calculation is complete. Retrieval of data from a previous assay is not possible, nor is it possible to give the signal-response range of the Amerlite standard curve, because the data are presented as a "percentage of full scale," but in these terms the range is from 0.01% at zero to 40% at 200 milli-int. units/L.
Patients' samples. The serum samples used in the study had been sent to the laboratory for routine thyroid-function tests. Once the sera were separated, the specimens were stored in aliquots at -18 #{176}C until analysis.
Results
Detection limit: The detection limit for each assay, determined by replicate analyses of the zero standard, was defined as the mean ±2.5 SD of the 20 replicates. For the Amerlite assay this was 0.04 milli-int. unitfL; for the Delfia, 0.02 milli-int. unit/L. The performances claimed for the assaysby the manufacturers are "better than" 0.04 milli-int. unit/L (mean ±2 SD of results for the zero standard) and 0.03 milli-int. unitlL (mean ±3 SD of results for the zero standard), respectively.
Precision: Table 1 Accuracy: To check the performance of these assays relative to that of others currently in use, we assayed by both methods some serum samples distributed by the United Kingdom External Quality Assurance Scheme for Thyroid Related Hormones (EQAS; Birmingham, U.K.) and compared the results with the target values assigned to the samples. The results are presented in Table 2 .
Results for samples from various clinical groups. Samples from subjects who had been classified clinically as euthyroid (n = 45), hyperthyroid (n = 14), hypothyroid (n = 12), or as having nonthyroidal illness (n = 22), were assayed by both methods. Figure 2 summarizes the results and relates them to the manufacturers' suggested reference intervals.
Discussion
For maximum clinical benefit from the use of TSH assays, a very sensitive and reproducible assay is needed. Both The assays are precise over the range examined here, with batch-to-batch reproducibility very good for both assays at the concentrations examined (Delfia assay CVs <6.0%, Ainerlite assay CVs <5.0%). The work of Browning et al. (7) suggests that, for thyrotropin, the calculated analytical goal for CV for optimal patient care is 8.1%. Both of these assays meet this goal over a wide range of values. Within-batch imprecision is sufficiently low to justi- recovery is therefore unlikely to lead to clinically mislead-(86%) ing results.
7.5
Results by the two methods generally correlated well, and We attempted to assess the accuracy of the two methods by analyzing samples supplied by EQAS. Both methods gave values consistently lower than the ALTM (derived mainly from laboratories using sensitive radiolabeled m assays), over the range 1.0 to 9.0 milli-int. unitWL. The reason for this negative bias is not clear, but it appears that at all concentrations we examined, analytical recovery of added TSH is between 90 and 96% for Delfia, 78 to 88% for Amerlite. Although there is no evidence that this underrecovery would cause problems of interpretation, the underlying reason for the discrepancy is being sought.
+
In terms of the clinical utility of the two assays, Figure 2 + illustrates the excellent discrimination between euthyroid and hyperthyroid subjects, and between euthyroid and hypothyroid patients, for both assays.
One clinically hyperthyroid patient with co-existing chronic renal failure had a TSH value well within the euthyroid range, as measured by either technique. Subsequent analysisrevealed increased values for total thyroxin * and free thyroxin index, but total triiodothyrornne within + the reference interval.
The group of subjects with nonthyroidal illness (covering So a wide range of conditions requiring hospitalization) were interesting in that the TSH concentrations of all but one #{149} exceeded the lower reference limit, despite a wide range of total thyroxmn concentrations (23 to 204 nmol/L). This suggests that TSH results from such assays might have a role in clarifying thyroid-fi.inction status in a group of patients for whom this has been a difficult problem.
0
In conclusion: We find both assays to be reliable, easy to use, and capable of giving very sensitive and precise measurements of TSH weu within one working day. A 96-well run (one plate) takes 5 h for Delfia (including a 4-h incubation), 4 h for Amerlite. The principal potential problem we found is the apparent under-recovery of added TSH, but we believe that this does not adversely affect clinical interpretation. Although these techniques require specific instrumentation, in both cases a series of other analytes can also be assayed, and either system could thus form a viable alternative to the use of radioisotopes in the laboratory.
